Chart, Financials, Historical Prices, Industry, Insider, Messages, Options, Profile, Reports, Research, SEC Filings, more...

Report Screener | Stock Screener | Bond Screener | Fund Screener

Report Search Results As of 10-Feb-2010
New Screen 

All Reports | Brokerage Reports | Independent Reports
All Reports (Showing 1 to 10 of 34)
Release
Date
 [down]
Contributor Author Title Pages Price StarMine Author Rating More Info
EPS Accuracy * Portfolio Return **
9-Feb-10New Constructs, LLCN/AVRTX: Risk/Reward Rating: Full Report: Cash Truth Behind the Reported Earnings19$10  View Abstract
9-Feb-10EconomicInvestorN/A"The Economy Matters" Report for VRTX: the economy's impact on VRTX's price and risk, featuring the powerful EconomicInvestor Star Rating6$15  View Abstract
8-Feb-10Market EdgeN/AMarket Edge Equity Research Report4$10  View Abstract
7-Feb-10Wright ReportsN/AWright Industry Averages: Health, Medicine and Pharmaceuticals (North America)100$169  View Abstract
7-Feb-10Wright ReportsN/AWright Industry Averages: Health, Medicine and Pharmaceuticals (United States)98$169  View Abstract
5-Feb-10Ford Investor Services, Inc.N/AValue Graph: VERTEX PHARMACEU -- VRTX1$4  View Abstract
5-Feb-10Jefferson ResearchN/AJefferson Research Financial Sonar Report. A detailed analysis of the current fundamental performance of VERTEX PHARMACEUTICALS INC including Earnings Quality, Cash Flow Quality, Operating Efficiency, Balance Sheet Quality and Valuation.11$20  View Abstract
5-Feb-10Ford Investor Services, Inc.N/AIndustry Value Graph: ABII , CELG , ENZN , KNDL , LIFE , MATK , ONTY , VRTX -- DRUGS3$4  View Abstract
3-Feb-10Wright ReportsN/AWright Investors Service Comprehensive Report for Vertex Pharmaceuticals Inc43$65  View Abstract
1-Feb-10Roth Capital Partners, Inc.Edward NashAchillion Corporate Update: Achillion Growing On All Fronts6$25  View Abstract
Next 20

Brokerage Reports (Showing 1 to 5 of 5)
Release
Date
 [down]
Contributor Author Title Pages Price StarMine Author Rating More Info
EPS Accuracy * Portfolio Return **
1-Feb-10Roth Capital Partners, Inc.Edward NashAchillion Corporate Update: Achillion Growing On All Fronts6$25  View Abstract
13-Jan-10Roth Capital Partners, Inc.Research DepartmentMorning Call Summary10$25  View Abstract
12-Jan-10Roth Capital Partners, Inc.Edward NashPositive Data Unrewarded, Creates A Strong Buying Opportunity5$10  View Abstract
12-Jan-10Thomson StreetEventsN/AVRTX - Event Transcript of Vertex Pharmaceuticals Incorporated conference call, Jan. 12, 2010 / 5:30pm ET5$75  View Abstract
30-Mar-09First GlobalLe Grand FromagFirst Global's Le Grand Fromage: Eats shoots and leaves6$30  View Abstract

Independent Reports (Showing 1 to 10 of 29)
Release
Date
 [down]
Contributor Author Title Pages Price More Info
9-Feb-10New Constructs, LLCN/AVRTX: Risk/Reward Rating: Full Report: Cash Truth Behind the Reported Earnings19$10View Abstract
9-Feb-10EconomicInvestorN/A"The Economy Matters" Report for VRTX: the economy's impact on VRTX's price and risk, featuring the powerful EconomicInvestor Star Rating6$15View Abstract
8-Feb-10Market EdgeN/AMarket Edge Equity Research Report4$10View Abstract
7-Feb-10Wright ReportsN/AWright Industry Averages: Health, Medicine and Pharmaceuticals (North America)100$169View Abstract
7-Feb-10Wright ReportsN/AWright Industry Averages: Health, Medicine and Pharmaceuticals (United States)98$169View Abstract
5-Feb-10Ford Investor Services, Inc.N/AValue Graph: VERTEX PHARMACEU -- VRTX1$4View Abstract
5-Feb-10Jefferson ResearchN/AJefferson Research Financial Sonar Report. A detailed analysis of the current fundamental performance of VERTEX PHARMACEUTICALS INC including Earnings Quality, Cash Flow Quality, Operating Efficiency, Balance Sheet Quality and Valuation.11$20View Abstract
5-Feb-10Ford Investor Services, Inc.N/AIndustry Value Graph: ABII , CELG , ENZN , KNDL , LIFE , MATK , ONTY , VRTX -- DRUGS3$4View Abstract
3-Feb-10Wright ReportsN/AWright Investors Service Comprehensive Report for Vertex Pharmaceuticals Inc43$65View Abstract
31-Jan-10TheStreet.com RatingsN/ATheStreet.com Ratings Stock Report For: VERTEX PHARMACEUTICALS INC5$25View Abstract
Next 19

* EPS Accuracy is a measure of an analyst's ability to accurately estimate the EPS for a company.
** Portfolio Return is a measure of the performance of an analyst's recommendations relative to his peers.


Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.